Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immuno-Oncology: What To Watch At ASCO 2018

Executive Summary

Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.

Advertisement

Related Content

NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO
Merck Files Keytruda/Chemo Combo Early With FDA In 1L Squamous Lung Cancer
In The Hot Seat: Bristol Defends IO Position Amid Sliding Stock And Forecasts
Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy
Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space
Roche Gains With Tecentriq IMpower131 NSCLC Data, But For How Long?
Nektar's NKTR-214 IO Deal With Bristol Looks Even Sweeter With More Data
Celgene's CAR-T Leadership Goals Advance At ASH 2017

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123108

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel